Talkmed Group Ltd
SGX:5G3
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.355
0.5
|
Price Target |
|
We'll email you a reminder when the closing price reaches SGD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one 5G3 stock under the Base Case scenario is 0.31 SGD. Compared to the current market price of 0.44 SGD, Talkmed Group Ltd is Overvalued by 30%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Talkmed Group Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for 5G3 cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Talkmed Group Ltd
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Talkmed Group Ltd
Balance Sheet Decomposition
Talkmed Group Ltd
Current Assets | 92.7m |
Cash & Short-Term Investments | 85.7m |
Receivables | 5.5m |
Other Current Assets | 1.5m |
Non-Current Assets | 11.2m |
Long-Term Investments | 2.3m |
PP&E | 8.7m |
Other Non-Current Assets | 198k |
Current Liabilities | 24m |
Accounts Payable | 4.4m |
Other Current Liabilities | 19.6m |
Non-Current Liabilities | -3.1m |
Long-Term Debt | 4.1m |
Other Non-Current Liabilities | -7.2m |
Earnings Waterfall
Talkmed Group Ltd
Revenue
|
79.1m
SGD
|
Operating Expenses
|
-46.3m
SGD
|
Operating Income
|
32.8m
SGD
|
Other Expenses
|
-5.1m
SGD
|
Net Income
|
27.7m
SGD
|
Free Cash Flow Analysis
Talkmed Group Ltd
SGD | |
Free Cash Flow | SGD |
5G3 Profitability Score
Profitability Due Diligence
Talkmed Group Ltd's profitability score is 78/100. The higher the profitability score, the more profitable the company is.
Score
Talkmed Group Ltd's profitability score is 78/100. The higher the profitability score, the more profitable the company is.
5G3 Solvency Score
Solvency Due Diligence
Talkmed Group Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Score
Talkmed Group Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
5G3 Price Targets Summary
Talkmed Group Ltd
Dividends
Current shareholder yield for 5G3 is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
TalkMed Group Ltd. is an investment holding company, which engages in the provision of medical oncology, stem cell transplants, and palliative care services. The firm is a provider of medical oncology and palliative care health care services in Singapore. The firm operates through two segments: Oncology services, and Cellular and gene therapy related products and services. The Oncology services provide specialist doctors and clinical staff to Parkway Cancer Centre (PCC), a division of Parkway Hospitals Singapore Pte. Ltd. for the provision of specialist medical oncology services (consultancy services). The company also provides consultancy services to Thu Cuc International General Hospital (TCH), to enable TCH to operate a medical center for the provision of oncology services in Hanoi, Vietnam. The company also provides consultancy services to the patients in Beijing and Chongqing. Cellular and gene therapy-related products and services include the provision of goods and services related to cellular and gene therapy through its subsidiary, CellVec Pte. Ltd. (CellVec).
Contact
IPO
Employees
Officers
The intrinsic value of one 5G3 stock under the Base Case scenario is 0.31 SGD.
Compared to the current market price of 0.44 SGD, Talkmed Group Ltd is Overvalued by 30%.